Americas was Immucell’s largest region in fiscal 2025, bringing in $24.39M of $27.64M (88%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Americas | — | — | $22.89M | $24.39M | ||||
| United States | $17.02M | $15.95M | — | — | ||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | ||||
| Non-Us | — | — | $3.60M | $3.25M | ||||
| Other | $1.55M | $1.52M | — | — | ||||
| Other States | — | — | — | — | ||||
| Total | $18.57M | $17.47M | $26.49M | $27.64M |
Immucell brought in $27.64M from its two regions in fiscal 2025, the year ended December 31, 2025. That was up 4.3% from $26.49M in fiscal 2024. Americas was the largest at $24.39M (88.2%), ahead of Non-Us at $3.25M (11.8%).
Compared with fiscal 2024, Americas grew 6.5% to $24.39M, while Non-Us fell 9.6% to $3.25M.
Immucell began breaking out Americas in fiscal 2024 and Non-Us in fiscal 2024. Immucell stopped reporting United States ($15.95M in fiscal 2023) and Other ($1.52M in fiscal 2023) as separate regions.
Corporate Segment, Scours was Immucell’s largest segment in fiscal 2025, bringing in $27.45M of $27.64M (99%).
| Statement Business Segments | FY 2020 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Corporate Segment, Scours | — | — | $26.31M | $27.45M | |
| Scours | $18.41M | $17.29M | — | — | |
| First Defense® | — | — | — | — | |
| Unallocated | — | — | — | — | |
| Corporate Segment, Mastitis | — | — | $178.92K | $196.39K | |
| Mastitis | $154.56K | $177.74K | — | — | |
| Other | $1.46K | — | — | — | |
| Total | $18.57M | $17.47M | $26.49M | $27.64M |
Immucell brought in $27.64M from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 4.3% from $26.49M in fiscal 2024. Corporate Segment, Scours was the largest at $27.45M (99.3%), ahead of Corporate Segment, Mastitis at $196.39K (0.7%).
Immucell began breaking out Corporate Segment, Scours in fiscal 2024 and Corporate Segment, Mastitis in fiscal 2024. Immucell stopped reporting Scours ($17.29M in fiscal 2023), Mastitis ($177.74K in fiscal 2023) and Other ($1.46K in fiscal 2022) as separate segments.
First Defense® Product Line was Immucell’s largest product and service line in fiscal 2024, bringing in $26.31M of $26.49M (99%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|---|---|
| First Defense® Product Line | $18.93M | $18.41M | $17.29M | $26.31M | ||||
| First Defense Product Line | — | — | — | — | ||||
| Revenuefromcontractwithcustomerincludingassessedtax | — | — | — | — | ||||
| Other Animal Health | $309.88K | $156.01K | $177.74K | $178.92K | ||||
| Other Product Services | — | — | — | — | ||||
| Total | $19.24M | $18.57M | $17.47M | $26.49M |
Immucell brought in $26.49M from its two product and service lines in fiscal 2024, the year ended December 31, 2024. That was up 51.6% from $17.47M in fiscal 2023. First Defense® Product Line was the largest at $26.31M (99.3%), ahead of Other Animal Health at $178.92K (0.7%).
From fiscal 2021 to 2024, combined revenue from these lines grew from $19.24M to $26.49M, a compound annual growth rate of 11.2%. First Defense® Product Line's share of the total rose from 98.4% to 99.3%.
Immucell (ICCC) reports its revenue by geography, by statement business segments and by product and service. In fiscal 2025, Americas was its largest region, bringing in $24.39M (88.2% of the total), followed by Non-Us at $3.25M (11.8%).
Americas was Immucell's largest region in fiscal 2025, bringing in $24.39M, or 88.2% of the $27.64M total across its two regions.
Corporate Segment, Scours was Immucell's largest segment in fiscal 2025, bringing in $27.45M, or 99.3% of the $27.64M total across its two segments.
First Defense® Product Line was Immucell's largest product and service line in fiscal 2024, bringing in $26.31M, or 99.3% of the $26.49M total across its two product and service lines.
Americas grew faster than Non-Us in fiscal 2025, up 6.5% from $22.89M to $24.39M. Non-Us fell 9.6% to $3.25M.
Every figure comes from Immucell's annual financial filings, as reported. Each line keeps the name Immucell gives it, and years follow its fiscal calendar.
Immucell's revenue by geography goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.